We have previously shown that the human ETS1 protein (p51-ETS1), when ectopically expressed in colon cancer cell lines, is able to reduce its tumorigenicity without aecting its growth properties. To understand the mechanism of tumor reduction, we have expressed two dierent forms of ETS1 in colon cancer cell lines. Data presented in this paper indicate that the naturally occurring spliced variant protein, p42-ETS1, lacking the region encoded by ETS1 exon VII, represses the tumorigenicity, while p51-ETS1 reduces the tumorigenicity. Repression of tumorigenicity mediated by p42-ETS1 appears to be caused by its ability to induce apoptosis in epithelial cancer cells. This work can have profound medical signi®cance in that it may open up new insights into the potential role of the p42-ETS1 in the induction of apoptosis in epithelial cell cancers and may provide a rationale for its use for potential gene therapy experiments to initiate cell death in cancer cells.
Introduction
Cancer is a multistep disease involving a series of genetic alterations that result in the loss of the control and regulation of cell proliferation and dierentiation. Such genetic alterations include the activation of oncogenes and the loss of tumor suppressor gene activity. Our understanding of cancer has been greatly facilitated by the study of retroviral transforming genes and their cellular homologs. For the past years, we and others have focused on the isolation and characterization of the ets gene family and its role in cell proliferation and dierentiation, and molecular etiology of cancer Wasylyk et al., 1993; Janknecht and Nordheim, 1993) .
The ETS1 gene encodes two distinct proteins, a 51 kDa protein encoded by full-length mRNA, and a 42 kDa protein encoded by an alternatively spliced mRNA lacking exon VII (Jorcyk et al., 1991; Koizumi et al., 1990) . ETS1 proteins are nuclear, acidic and rapidly turned over (t 1/2*90 min), and function as sequence speci®c (-GGAA-) transcription factors Wasylyk et al., 1993; Janknecht and Nordheim, 1993) . ETS1 has been shown to bind to the -GGAA-sequences in the promoter and enhancer regions of a number of cellular and viral genes and thus to control their expression.
The 51 kDa but not 42 kDa protein is phosphorylated as a result of the elevation of intracellular Ca 2+ ion concentration (by treatment with ionomycin or during early stages of mitosis), indicating that the major phosphorylation sites are encoded in exon VII (Rabault and Ghysdael, 1995) . Both 42 kDa and 51 kDa ETS1 bind to DNA with similar anity and dissociate at dierent rates (Fisher et al., 1994) . P42-ETS1 lacks the inhibitory domain involved in the intramolecular folding (Wasylyk et al., 1992; Jonsen et al., 1996) . Furthermore, phosphorylation of ETS1 has been shown to inhibit its DNA binding properties (Rabault and Ghysdael, 1995; Fisher et al., 1994) . These results suggest that the p42-ETS1 is a stronger transcription factor than p51-ETS1.
We have previously shown that the ectopic expression of p51 human ETS1 protein in two dierent colon cancer cell lines (DLD1, HCT 116) is able to reduce their tumorigenicity. However, a mutant form of p51 human ETS1 lacking transcriptional activity was not able to reduce the tumorigenicity of colon cancer cell lines .
To understand the mechanism of tumor reduction, we have ectopically expressed p42-ETS1 in DLD1 colon cancer cell line using highly controllable tetracycline-dependent expression system. Data presented in this paper demonstrate that the p42-ETS1 expression can be tightly controlled by tetracycline. DLD1 cells expressing p42-ETS1 do not form tumors in nude mice and undergo apoptosis when the cells were grown in low serum media. By contrast, DLD1 cells expressing mutant p42-ETS1 (mutation in the transactivation domain) do not undergo apoptosis. Furthermore, DLD1 cells expressing p51-ETS1, suppress tumorigenicity but do not undergo apoptosis. These results support the hypothesis that suppression of tumorigenesis by p42-ETS1 is mediated by its ability to induce apoptosis.
Results

Isolation and characterization of DLD-1 transfectants expressing p42-ETS1
We have previously shown that the ectopic expression of p51 human ETS1 protein in two dierent colon cancer cell lines (DLD1, HCT 116) is able to reduce their tumorigenicity . However, we could not rule out the possibility that the reduction of tumorigenicity could be partially due to clonal variation among selected cell lines. To rule out this possibility, we have used tetracycline controlled vector system (Gossen and Bujard, 1992; Resnitzky et al., 1994) to express ETS1 proteins in DLD1 cells. This was accomplished by generating stable DLD1 cell lines expressing high levels of tTA activity (DLD1-tTA1 and tTA5) which was controlled very tightly by tetracycline. The relative luciferase activity of the clones in the absence or presence of tetracycline was 103-and 56-fold high, respectively. When these transfectants were examined for their tumorigenicity in nude mice, they showed no signi®cant changes among parental DLD1, DLD-1-tTA1 and tTA5 cell lines (data not shown). Both DLD1-tTA-1 and tTA5 cells were transfected with the p42-ETS1 expression plasmid DNA under the control of the tet operator. Several clones were isolated from both tTA5 and tTA1 cell lines (DLD1-tTA5DVII-E1-3, E1-25; DLD1-tTA1DVII-E1-2, 5, 6 and 19), and the expression level of ETS1 was examined by immunoprecipitation and results are shown in Figure  1 . The 42 kDa protein (p42), was recognized by ETS1 antibodies raised against three dierent epitopes along the ETS1 protein. As expected, this protein was not recognized by K17C antibodies prepared against an exon VII of ETS1 peptide epitope. These results demonstrate that the 42 kDa protein expressed in several transfectants shown in Figure 1a is encoded by ETS1 cDNA. We selected dierent clones expressing dierent levels of p42-ETS1 protein for further analysis (Figure 1a ).
ETS1 expression is tightly regulated by tetracycline
To ®nd out if the p42-ETS1 expression could be regulated by tetracycline, transfectants were grown in the presence of dierent amounts of tetracycline, and p42-ETS1 expression was examined by metabolic labeling of cells with 35 S-methionine and by immunoprecipitation as described in Materials and methods. As shown in Figure 1b , the p42-ETS1 protein expression is totally suppressed by 0.1 mg/ml tetracycline ( Figure 1b) . To determine the time required for the p42-ETS1 induction following tetracycline withdrawal, we analysed the p42 expression; and results are shown in Figure 1c . Induction of p42-ETS1 protein appears 4 ± 8 h after tetracycline withdrawal and is sustained up to 2 months ( Figure 1c , lanes 2 ± 4, data not shown). The expression of p42-ETS1 is totally suppressed in the presence of tetracycline (in all of the transfectants examined) and induced within 8 h following withdrawal.
Properties of p42-ETS1 protein
We have shown that the p51-ETS1 protein is localized in the nucleus and binds to -GGAA-motif and functions as a transcription factor Wasylyk et al., 1993; Koizumi et al., 1990; Fisher et al., 1992) . To determine localization of p42-ETS1 protein expressed in DLD1 cells, DLD1-tTA1DVII E1-6 cells expressing the p42-ETS1 protein were stained with ETS1 speci®c antibody. Immuno¯uorescence analysis of these cells indicates that the p42-ETS1 protein is localized in the nucleus (data not shown). In the presence of tetracycline, no nuclear staining was observed. Nuclear staining was also not observed with the parental DLD1 or DLD1-tTA 1 or 5 cells. Taken together, these results demonstrate that antibody staining is speci®c and p42-ETS1 is localized in the nucleus. . Independent DLD-1 transfectants expressing p42-ETS1 at dierent levels (a) were generated as described in Materials and methods. Tetracycline dependent expression of p42-ETS1 in DLD-1 cells is shown in Figure 1b . tTA DVII E1-19 transfectants were split overnight. Cells were washed twice with PBS and incubated with media containing indicated amounts of tetracycline. Cells were metabolically labeled with 35 S-methionine for 2 h and p42-ETS1 protein was identi®ed by immunoprecipitation. The data show that p42 ETS1 protein formation is suppressed by a 0.1 mg/ml concentration of tetracycline (b). Induction of p42-ETS1 protein appears between 4 ± 8 h after tetracycline withdrawal and is sustained for up to 24 h (c, lanes 2 ± 4). p42-ETS1 expression is not detectable in the presence of tetracycline (lane 1)
p42-ETS1 represses tumorigenicity
To determine the tumorigenic potential of p42-ETS1 transfectants, cells were grown in the presence of tetracycline for 3 days and were injected into thē anking region of athymic nude mice containing either 60-day release tetracycline (50 mg/pellet) or placebo pellets). In the absence of tetracycline (p42-ETS1 is expressed) tumors were not observed even up to 6 months ( Figure 2 , data not shown), whereas in the presence of tetracycline (p42-ETS1 is not expressed) DtTA1-DVIIE1-6 cells formed tumors in nude mice within 4 weeks. Transfectants expressing lower levels of p42-ETS1 were able to form small tumors (Table 1) indicating that the tumor suppression is dependent on the level of p42 expression. Taken together, these results demonstrate that tumor suppression is due to the induction of p42-ETS1 rather than the clonal variation observed among transfectants.
p42-ETS1 induces apoptosis in DLD-1 cells
To understand the mechanism of p42-ETS1 mediated tumor suppression, we compared the cell proliferation rate of p42-ETS1 transfectants in the presence or absence of tetracycline. When cells were grown in the presence of high concentrations of serum, no signi®cant dierences in cell number were observed among transfectants. However, under low serum concentrations (0.1% FBS), the p42-ETS1 transfectants showed dramatic morphological changes characteristic of apoptosis (Figure 3) . Furthermore, the number of live cells were signi®cantly higher in media containing tetracycline than in media without tetracycline indicating that the reduction in cell number is mediated by induction of p42-ETS1. Morphological changes characteristic of apoptosis were further examined, and results are shown in Figure 3 . Under low serum conditions, cells expressing p42-ETS1 become round and condensed and detach from the substratum. When these cells were stained with acridine orange, condensed nuclear staining characteristic of apoptosis was observed (Figure 3 IIc). Condensed nuclei are readily apparent only in DLD-1 cells expressing p42-ETS1 protein and not in cells where p42-ETS1 protein is turned o by tetracycline. These results were further con®rmed by electron microscopy, which also showed that cells expressing p42-ETS1 have condensed nuclei (Figure 3 IV) . To further con®rm that the transfectants expressing p42 ETS1 undergo apoptosis. DNA samples from cells growing in low serum concentrations expressing p42 ETS1 were analysed. As shown in Figure 3 III, cells expressing p42-ETS1 showed DNA laddering characteristic of apoptosis. Taken together, these results demonstrate that the DLD1 cells expressing high levels of p42-ETS1 undergo apoptosis. Mutations were introduced in the transactivation domain (TA) of the p42-ETS1 protein. The amino acid substitutions were from Glu to Gly and Asp to His similar to those we reported in the TA domain of the 6 DtTA1DVII E1-6 cells were injected subcutaneously into the right anterior¯ank area of the athymic nude mice. Photographs were taken after 2 months of the injection Tumor incidence in nude mice of DLD-1 transfectants expressing p42-ETS1. tTA1 and tTA5 are two independent DLD-1 tTA transfectants expressing tetracycline repressor activator proteins. p42-ETS1 proteins were ectopically expressed in these two transfectants and independent transfectants expressing dierent amounts of p42-ETS1 were used for studying the tumorigenicity in nude mice. A slow release tetracycline or placebo pellets were used as described in Figure 2 legend. Mice were monitored on a weekly basis and tumor incidence after 2 months of injection is shown. The tumorigenicity of DLD-1 cells was suppressed by ectopic expression of p42-ETS1. The degree of suppression was dependent on the level pf p42-ETS1 expression. Threshold level of p42-ETS1 is necessary to suppress tumorigenicity of DLD-1 cells. The tumor suppression of DLD-1 cells is due to expression of p42-ETS1 rather than clonal variation among ETS1 transfectants. *ND: not determined p51-ETS1 protein . The resulting mutant p42-ETS1 protein lost its ability to induce apoptosis indicating the importance of the TA domain in cell death (data not shown).
Discussion
ETS1 is a cellular homolog of the viral ets oncogene derived from the E26 avian leukosis retrovirus. Since the publication of our reports indicating that ets exists as a family of genes, a number of ets-related genes have been identi®ed from dierent species (420 family members) by our laboratory and others Wasylyk et al., 1993; Janknecht and Nordheim, 1993) . The ets family members (i) have variable anities for the -GGAA/ T-sequence core present in target genes, (ii) interact with other cellular proteins, (iii) are modi®ed by phosphorylation, and (iv) can act as both transcription enhancers and repressors Wasylyk et al., 1993 ; Janknecht and Nord-
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Figure 3 p42-ETS1 induces apoptosis in DLD-1 cells. DtTA1 and its p42 transfectants (1610 5 ) were split into 6-well tissue culture plates in 15% FBS RPMI 1640 media overnight. The cells were washed by PBS twice and then grown in 0.1% FBS RPMI 1640 media in the presence or absence of tetracycline. Phase contrast photography was taken after 72 h. p42-ETS1 expressing cells showed a morphological change (I). (II) DtTA DVII E-6 transfectants were grown in the presence or absence of tetracycline containing 0.1% fetal calf serum. After 3 days supernatants were removed. Cells were stained with acridine orange. A, +tetracycline; B, 7tetracycline. In frame C, round cells which detach easily during PBS wash were analysed for apoptosis. Round cells were released by gentle tapping of DtTA DVII E-6 transfectants in PBS. Cells were pelleted and stained with acridine orange. Condensed nuclear staining characteristic of apoptosis were apparent only when p42-ETS1 is made in DLD-1 cells. (III) DLD-1 transfectants were grown in the presence or absence of tetracycline containing 0.1% fetal calf serum for 3 days. Cells were harvested, washed with PBS, and genomic DNA was isolated for DNA laddering. DNA ladder characteristic of apoptosis were apparent in cells expressing p42-ETS1. (IV) Electron micrographs of DLD-1 cells expressing (frame B) or not expressing (frame A) p42-ETS1. Condensed nuclei are readily apparent in DLD-1 cells expressing p42-ETS1, whereas same cells when p42-ETS1 expression is turned o by tetracycline exhibit normal nuclear morphology. Morphological changes, nuclear condensation, and DNA laddering of DLD-1 cells expressing p42-ETS1 demonstrate that p42-ETS1 induces apoptosis in DLD-1 cells
heim, 1993). These observations favor the possibility that members of the ets family of genes regulate their target gene activities independently of one another. Therefore, dierent members of the ets family can compete for ets binding sites and, thereby, facilitate the activation of target genes in dierent cell and tissue types. We have previously shown that the ETS1 protein is expressed at higher levels in adult human lymphoid tissue than in other tissues (Bhat et al., 1989 Romano-Spica et al., 1994) . Our data also indicate that ETS1 is expressed at high levels in resting T-cells and not in activated T-cells Romano-Spica et al., 1994) , suggesting that it may regulate the expression of genes invovled in the maintenance of the quiescent state (Romano-Spica et al., 1995; Bhat et al., 1996) . Given this function, we reasoned that ETS1 has an important role in controlling cell death and set about identifying cell lines that are highly tumorigenic and do not normally express ETS1 to test this hypothesis. We have observed that ETS1 is not expressed in several human epithelial tumordrived cell lines (Romano-Spica et al., 1994; Suzuki et al., 1993) , and that overexpression of ETS1 in transfected DLD-1 cells reduces the transformed phenotype and tumorigenicity . The tumorigenic properties of these transfectants were inversely correlated to the level of ETS1 protein produced. DLD-1 transfectants that expressed high levels of ETS1 generally produced no tumors in nude mice, whereas parental and neotransformants (controls) formed tumors within the same 3-week incubation period. To avoid any clonal variation, we have isolated stable transfectants that contain cDNA encoding either p51-ETS1 or p42-ETS1, regulated by the tetracycline-inducible promoter. Clones expressing either the p51 or p42 protein repress tumorigenicity of the transformed cells; however, only cells expressing the p42 protein become apoptotic. The p42-ETS1 protein induced apoptosis in cells maintained in low serum media. In contrast, the p51-ETS1 protein does not promote apoptosis. Based on this unique biological distinction between the two major isotypes of ETS1, we must assess their individual contributions to normal cellular homeostasis. Programmed cell death is essential in many physiological processes, such as embryonic development and clonal selection by the immune system. The attractive idea of whether tumor cells can be eliminated by inducing programmed cell death, has recently been explored. Although we are examining apoptosis in epithelial cells that do not normally express ETS1, this system provides a model that will allow us to investigate the regulation of apoptosis in tumor cells and will generate useful information on mechanisms that can be exploited to promote cell death in tumor cells. In summary, we have established a model system in epithelial cells showing that the two major ETS1 protein isotypes have overlapping (both repress the tumorigenic phenotype of epithelial cells) and unique (only the p42-ETS1 protein promotes apoptosis) biological properties. Understanding the mechanism of p42-ETS1-induced apoptosis in epithelial cells will provide information about its function in T-cells, cell systems where is it normally expressed.
Materials and methods
Plasmids
Tetracycline vector system including: PUHD10-3, PUHD15-1 neo and PUHC13-3 was obtained from Dr Bujard (Gossen and Bujard, 1992; Resnitzky et al., 1994) . Full length human wild type, mutant and p42-ETS1 cDNA (Fisher et al., 1994; Suzuki et al., 1995; Watson et al., 1988) containing BglII sites at either ends was generated by PCR using the following primers: sense 5'-CCAGATCT-CACCATGAAGGCGGC-3' and antisense 5'-CCAGATC-TAGTGCCATCACTCGTCG-3'. These cDNAs were cloned in the BamHI site of PUHD10-3. For the construction of mutant p42-ETS1 plasmid, a 2.8 Kb fragment was isolated by A¯3 digestion of pUHD10-3 mutant p51-ETS1 plasmid. This 2.8 Kb fragment was ligated with the 0.3 Kb and 1.2 Kb fragments which are isolated from the A¯3 digestion of pUHD10-3 p42-ETS1 plasmid. The identities of each ETS1 plasmid DNA were further con®rmed by DNA sequencing.
Cell culture and transfection
Isolation and characterization of DLD-1 transfectants expressing ETS1 protein under control of tetracycline repressor Vp16 activator protein (tTA). The human colon carcinomas cell line DLD-1 was transfected with PUHD 15-1neo by using lipofectamine (LTI) following the protocol suggested by the manufacturer. Transfectants were selected with G418 (400 mg/mg). The clones expressing tTA were measured using tet-operator-luciferase plasmid (pUHC13-3) as described before (Gossen and Bujard, 1992; Resnitzky et al., 1994) . Clones expressing high levels of tTA activites in the absence compared to the presence of tetracycline were selected for expressing ETS1 proteins. Two independent clones (DtTA1 and DtTA5) were co-transfected with tet-op ETS1 expression vectors and Ptk hygromycin vector and multiple clones were selected in the presence of tetracycline (2 mg/ml), G418 (400 mg/mg) and hygromycin (100 mg/ml) for 4 weeks. Clones were grown in the absence of tetracycline overnight. They were characterized by metabolic labeling with 35 Smethionine and immunoprecipitation with ETS1 antibodies. The identity of p42-ETS1 is further con®rmed by lack of reactivity against exon VII ETS1 speci®c antisera. Clones expressing dierent levels of p42-ETS1 were used for further analyses.
Cell labeling, immunoprecipitation and tumorigenesis studies in nude mice
These studies were conducted as described previously .
Apoptosis study
Morphology Cell (1610 5 ) were seeded in 6-well plates in 15% FBS RPMI 1640 media overnight and were washed with PBS. The media were replaced by RPMI 1640 media containing 0.1% FCS, with or without tetracycline. Cells were examined for morphology and cell lysis. At the appropriate time, cells were stained with acridine orange (Sigma) to observe chromosomal condensation.
Electron microscopy The cells were seeded and grown in the low serum as described as above. After 3 days, the cells were collected for the electron microscopy study. Standard electron microscopic procedures were used.
DNA laddering Cell were cultured as described above, and at dierent intervals cells were collected and lysed in 50 ml of lysis buer (50 mM Tris HCl, PH8, 10 mM EDTA, 0.5% sodium lauryl sarcosine, and 0.5 mg/ml of proteinase K) at 508C for 1 h RNaseA (0.5 mg/ml) was added and incubated for an additional hour. All the DNA samples were electrophoresed in 1% agarose gel in 0.56TBE buer, and DNA fragments were visualized by ethidium bromide staining.
